EZH2 A682G

In this study, we performed an in-depth spatio-temporal analysis of EZH2 mutations in FL using tissue- and liquid biopsy samples and identified gain-of-function mutations in a considerably higher proportion of patients than previously reported (42% vs 27%) owing to the ability of this approach to resolve spatial heterogeneity. This expands the subset of FL patients who most likely would benefit from EZH2 inhibitor therapy and highlights the need for parallel EZH2 testing in LB and TB samples when considering EZH2 inhibitor therapy. EZH2, ctDNA, Follicular lymphoma